Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer… Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Jul 14, 2015
Warning! 5 Heavily-Followed Dividend-Paying Stocks to Avoid
This list will surprise you. Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s. Feb 5, 2015
Some Wiggle Room, Please
Lots of earnings reports out. Let’s go around the horn. Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems. Dec 22, 2014
Dividend Increases for the Week Ending December 19
Let's take a look at dividend increases for the week ending December 19. Aug 26, 2014
Price Is Almost Always Different Than Value
This key tenet behind stock market investing success is worth remembering. Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Let's talk about whether tax inversions are a core part of the freedom that is innate to the American character.